An oral epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer in patients with initial activating epidermal growth factor receptor mutations as well as the T790M dominant acquired resistance mutation.
If you have a Hayes login, click here to view the full report on the Knowledge Center.